BioCardia Gains Japanese Patent for Heart3D Imaging Technology

BioCardia ( (BCDA) ) has shared an announcement.

On April 28, 2026, BioCardia announced that Japanese authorities had allowed a patent titled “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation” covering its proprietary Heart3D fusion imaging software. The patent protects technology that overlays preoperative CT or MRI-based 3D heart images onto orthogonal 2D views to generate a 3D model for use within or near the sterile field, aiding navigation and documentation during interventional procedures.

The newly allowed Japanese patent strengthens BioCardia’s intellectual property around Heart3D, which is intended to support its CardiAMP cell therapy for ischemic heart failure and the Helix intramyocardial delivery system. This move reinforces the company’s technology stack for cardiac biotherapeutic interventions in Japan as it works toward regulatory submissions, building on encouraging feedback from Japan’s regulator and existing clinical evidence underpinning CardiAMP’s safety and efficacy profile.

The most recent analyst rating on (BCDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

Spark’s Take on BCDA Stock

According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, persistent losses, and continued cash burn with financing dependence). Technical indicators are also soft, with negative momentum and price below key moving averages. Offsetting these are a moderately constructive earnings/regulatory narrative and positive recent regulatory progress/catalysts, but they do not fully mitigate near-term funding and execution risk.

To see Spark’s full report on BCDA stock, click here.

More about BioCardia

BioCardia, Inc., headquartered in Sunnyvale, Calif., is a biotechnology company focused on cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its pipeline includes CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation platforms, with Heart3D fusion imaging as a forthcoming enabling technology.

The company positions itself as a partner for biotherapeutic delivery with peers developing advanced biologic therapies and is advancing three cardiac clinical-stage product candidates. Its CardiAMP Cell Therapy has FDA Breakthrough designation and is supported by public and reimbursement backing, including the Maryland Stem Cell Research Fund and U.S. Centers for Medicare and Medicaid Services.

Average Trading Volume: 67,154

Technical Sentiment Signal: Sell

Current Market Cap: $12.69M

For detailed information about BCDA stock, go to TipRanks’ Stock Analysis page.